EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Interim Financial Statements
Interim Financial Statements
| a. | reviews and determines the Company’s practice with respect to review of interim financial statements by the external auditors; |
|---|
| b. | conducts all such reviews and discussions with the external auditors and Management as it deems appropriate; and |
|---|
| c. | makes recommendations to the Board respecting approval of the interim financial statements. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.